CHINARES PHARMA (03320) announced that its subsidiary, China Resources Boya Bio-Pharmaceutical Group Co., Ltd., recorded operating revenue of RMB 1.474 billion for the first nine months ending September 30, 2025, representing an 18.4% year-on-year increase. However, net profit declined by 16.8% YoY to RMB 343 million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.